Cargando…
Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
BACKGROUND: Recent developments in MIBC treatment suggest good efficacy of bladder sparing treatment combined with immune checkpoint inhibitor. However, there is no standard treatment mode. A retrospective analysis was conducted to reveal the efficacy and safety of PD-1 inhibitor in combination with...
Autores principales: | Xu, Chao, Zou, Wen, Zhang, Lei, Xu, Ran, Li, Yuan, Feng, Yeqian, Zhao, Runtian, Wang, Yinhuai, Liu, Xianling, Wang, Jingjing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239884/ https://www.ncbi.nlm.nih.gov/pubmed/37283762 http://dx.doi.org/10.3389/fimmu.2023.1162580 |
Ejemplares similares
-
Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review
por: van Hattum, Jons W., et al.
Publicado: (2021) -
Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022) -
Association between radiotherapy and prognosis in patients with small cell carcinoma of the bladder undergoing bladder-sparing surgery
por: Liang, Fuchao, et al.
Publicado: (2023) -
Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
por: Guo, Ya, et al.
Publicado: (2022) -
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
por: Cheng, Wen, et al.
Publicado: (2018)